KI-67 PROLIFERATING INDEX AND HISTOLOGICAL GRADE, TYPE AND STAGE OF COLORECTAL CARCINOMA
Abstract
Background: The objective of this study was to assess the relationship of histological type, grade andstage of colorectal carcinoma with proliferative activity as measured by Ki-67 LI. It was a descriptivestudy and conducted at the Department of Pathology, University of Health Sciences, Lahore. Methods:Ki-67 is a protein associated with cell proliferation and is expressed in all the phases of cell cycle exceptG0. In the present study, Ki-67 expression in 50 patients with colorectal adenocarcinomas was observedusing immunohistochemistry with monoclonal antibody MIB-1. Results: Ki-67 LI was high in well andmoderately differentiated adenocarcinomas (mean Ki-67 LI 392.50± 56.58 and 342.24±96.84respectively) as compared to poorly differentiated adenocarcinomas (mean Ki-67 LI 250.00±113.46). Ki-67 LI was high in non mucinous adenocarcinomas than mucin secreting and signet ring celladenocarcinomas (mean Ki-67 393.93±55.91 vs 220.00±49.72 and 200.00±79.05 respectively). As regardthe Dukes’ staging, Ki-67 LI was high in colorectal carcinomas in Dukes’ stage B than tumours in Dukes’stage C (Mean Ki-67 LI 360.13±90.03 vs 241.66±101.31 respectively). Conclusion: The proliferativeactivity as measured by Ki-67 antibody is related to histological type, grade and stage.Keywords: Colorectal carcinoma, Grade, Proliferation index, Immunohistochemistry, Ki-67References
Bisgaard LM. Young age colorectal cancer and identification
of hereditary non-polyposis colorectal cancer cohorts. Br J
Surg 2007;94:1055–6.
J Ayub Med Coll Abbottabad 2008;20(4)
http://www.ayubmed.edu.pk/JAMC/PAST/20-4/Uzma.pdf
Reza MM, Blasco AJ, Andradas E, Cantero R, Mayol J.
Systematic review of laparoscopic versus open surgery for
colorectal cancer. Br J Surg 2006;93:921–8.
Skjelbred F C, Sæbø M, Hjartaker A, Grotmol T, Hansteen LI,
Tveit MK, et al. Meat, vegetables and genetic polymorphisms
and the risk of colorectal carcinoma and adenomas. BMJ
Cancer 2007;7:228–34.
Soreide K, Janssen MAE, Soiland H, Korner.H, Baak APJ.
Microsatellite instability in colorectal cancer. Br J Surg
;93:395–406.
Conlin A, Smith G, Carey A. F, Wolf R. C, Steele CJR. The
prognostic significance of K-ras, p53, and APC mutations in
colorectal carcinoma. Gut 2005;54:1283–86.
Leslie A, Carrey FA, Pratt NR, Steele RJC. The colorectal
adenoma_carcinoma sequence. Br J Surg 2002;89:845–60.
Rosai J. Gastrointestinal tract In: Ackerman’s surgical
pathology. 9th ed. St. Louis: Mosby, 2004;p. 750–858.
Raraty MG, Winstanley JH. Variation in the staging of
colorectal carcinomas: a survey of current practice. Ann R Coll
Surg Engl 1998;80:188–91.
Gordon PH, Nivatvongs S. editors. Principles and practice of
surgery for the colon, rectum and anus. Missouri: Karen
Berger, 1992;p.503–20.
Oshima FTC, Iriya K, Forones MN. Ki-67 as a prognostic
marker in colorectal cancer but not in gastric cancer. Neoplasm
;5:420–4.
Urruticocechea A, Smith EI, Dowsett M. Proliferation Marker
Ki-67 in Early Breast Cancer. J Clin Oncol 2005;23:7212–20.
Bancroft J, Anderson G. Tissue Processing and Microtomy
including Frozen. In: Bancroft JD, Gamble M, editors. Theory
and practice of Histological techniques.5th ed. New York:
Churchill Livingstone, 2002; p. 85–107.
Key M. Immunohistochemical Staining Methods, 4th ed.
Avaiable from: http://pri.dako.com/08002_25may06_ihc_
guide_book.pdf
Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of
bcl-2 Oncoprotein Immunohistochemical Expression with
Proliferation Index and Histopathologic Parameters in
Colorectal Neoplasia. AppI Immunohistochem Mol Morphol
;8:175–82.
Valera. V, Yokoyama. N, Walter. B, Okamoto. H, Suda.T and
Hatakeyama. K. Clinical significance of Ki-67 proliferation
index in disease progression and prognosis of patients with
resected colorectal carcinoma.Br J Surg 2005;92:1002–7.
Ishida H, Sadahiro S, Suzuki T, Ishikawa K, Kamijo A, Tajima
T et al. Proliferative, infiltrative and metastatic activities in
colorectal tumours assessed by MIB-1 antibody. Oncology
;10:1741–5.
Lanza G Jr, Cavazzini L, Borghi L, Ferretti S ,Buccoliero F and
Rubbini M. Immunohistochemical assessment of growth
fraction in colorectal adenocarcinomas with monoclonal
antibody Ki-67. Relation to clinical and pathological variables.
Path Res Prac 1990;186:608–18.
Georgescu VC, Saftoiu A, Georgescu CC, Ciurea R, Ciurea T.
Correlation of Proliferation Markers, p53 expression and
Histological Findings in Colorectal carcinomas. J gastroenterol
and liver diseases 2007;16:125–9.
Jansson A, Sun XF. Ki-67 expression in relation to
clinicopathological variables and prognosis in colorectal
adenocarcinomas.APMIS 1997;9:730–4.
Shepherd AN, Richman IP, England J. Ki-67 derived
proliferative activity in colorectal adenocarcinoma with
prognostic correlations. J Pathol 1988;155:213–9.
Kyzer S, Gordon HP. Determination of proliferative activity in
colorectal carcinoma using monoclonal antibody Ki-67. Dis
Colon Rectum 1997;40:322–5.
Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el
Naggar AK, Assessment of Ki-67 derived tumour
proliferative activity in colorectal adenocarcinomas. Mod
Pathol 1994;1:17–22.
Petrowsky H, Sturm I, Graubitz O, Kooby AD, Staib-Sebler E,
Gog C et al. Relevance of Ki-67 antigen expression and K-ras
mutation in colorectal liver metastases. E J S O 2001;27:80–7.
.Michael-Robinson MJ, Reid EL, Puride MD, BiemerHuttmann EA, Walsh DM, Pandeeya N, et al. Proliferation
,Apoptosis and Survival in High Level Microsatellite
Instability Sporadic Colorectal Cancer. Clinical Cancer
Research 2001;7:2347–56.
